Chugai May Not Win Race For $500m Neuromyelitis Optica Market, But May Best Soliris On Ease Of Use

A Phase III study of Chugai Pharmaceutical Co. Ltd. ’s anti-IL-6 receptor monoclonal antibody (MAb) satralizumab for neuromyelitis optica spectrum disorder (NMOSD) has shown to, on top of immunosuppressive therapy, significantly reduce the risk of relapse by 62%, and by 79% in AQP4-positive patients. The MAb also demonstrated a good safety profile. T 

There are no current approved therapies for NMOSD, which is an inflammatory disease of the central nervous system in which there are episodes of inflammation and damage to the myelin that almost exclusively affect the optic nerves and spinal cord